Anticancer Drugs Oncology Pharmacology Physiotherapy

Olaparib (Description-17)

In this article we will discuss Olaparib (Description-17)

In this article, we will discuss Olaparib (Description-17). So, let’s get started.

Clinical Studies (1)

First-Line Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer

The efficacy of Olaparib was evaluated in SOLO-1 (NCT01844986), a randomized (2:1), double-blind, placebo-controlled, multi-center trial in patients with BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer following first-line platinum-based chemotherapy. Patients were randomized to
receive Olaparib tablets 300 mg orally twice daily or placebo. Treatment was continued for up to 2 years or until disease progression or unacceptable toxicity; however, patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider could derive further benefit from continuous
treatment, could be treated beyond 2 years. Randomization was stratified by response to first-line platinum-based chemotherapy (complete or partial response). The major efficacy outcome was investigator-assessed progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.